Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Buy" by Analysts

Key Points

• Consensus "Buy": Five analysts covering Adagene have given a consensus rating of Buy, with a split of one sell, two buy and two strong buy recommendations.
• Price target vs. market: The average 12‑month broker price target is about $7.67 versus a recent share price of $3.63 (12‑month range $1.30–$4.58), suggesting notable upside implied by analysts.
• Business profile: Adagene is a clinical‑stage biopharmaceutical focused on antibody‑based cancer and immune therapies, leveraging its Bihanc™ platform that combines phage display, structure‑based design and AI.

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) has been assigned a consensus rating of "Buy" from the five analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $7.6667.

Several research firms have recently weighed in on ADAG. Wall Street Zen upgraded shares of Adagene to a "hold" rating in a research report on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adagene in a research report on Wednesday, January 21st. Finally, Guggenheim initiated coverage on shares of Adagene in a research report on Monday, November 24th. They issued a "buy" rating and a $9.00 target price for the company.

Adagene Trading Down 1.6%

Adagene stock opened at $3.63 on Friday. Adagene has a 12-month low of $1.30 and a 12-month high of $4.58. The firm has a 50 day simple moving average of $2.88 and a 200-day simple moving average of $2.25.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Gordian Capital Singapore Pte Ltd lifted its stake in Adagene by 101.4% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 48,342 shares of the company's stock worth $96,000 after purchasing an additional 24,342 shares during the period. Citadel Advisors LLC acquired a new stake in Adagene during the third quarter valued at approximately $80,000. Exome Asset Management LLC bought a new stake in shares of Adagene in the 4th quarter valued at approximately $2,004,000. SmartHarvest Portfolios LLC acquired a new position in shares of Adagene in the 4th quarter worth approximately $73,000. Finally, Marex Group plc acquired a new position in shares of Adagene in the 2nd quarter worth approximately $47,000. 9.51% of the stock is currently owned by institutional investors and hedge funds.

About Adagene

Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene's pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene's research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.